Intellia Therapeutics (NASDAQ:NTLA) Releases Earnings Results, Beats Expectations By $0.03 EPS

Intellia Therapeutics (NASDAQ:NTLA) issued its earnings results on Thursday. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.03, Briefing.com reports. The firm had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. The firm’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same period last year, the business earned ($1.38) earnings per share.

Intellia Therapeutics Trading Up 4.3 %

Shares of NTLA traded up $0.69 during trading hours on Friday, hitting $16.69. 1,344,353 shares of the stock traded hands, compared to its average volume of 1,655,353. The business has a fifty day moving average of $19.28 and a 200-day moving average of $22.25. The firm has a market capitalization of $1.70 billion, a PE ratio of -3.02 and a beta of 1.81. Intellia Therapeutics has a 1-year low of $13.95 and a 1-year high of $34.87.

Wall Street Analyst Weigh In

NTLA has been the subject of a number of analyst reports. Robert W. Baird reduced their price objective on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a report on Friday, October 25th. The Goldman Sachs Group lowered their price objective on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Wedbush reaffirmed a “neutral” rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research note on Thursday. JPMorgan Chase & Co. lowered their price target on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Finally, Chardan Capital cut their price objective on Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating for the company in a report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Intellia Therapeutics has an average rating of “Moderate Buy” and an average price target of $57.94.

Insider Buying and Selling

In other news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.20% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.